Gene manipulation and transfer of the plasminogen and coagulation system in mice

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue 6, 1996, Pages 525-542

  Carmeliet, Peter ^a   Collen, Désiré ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

adenovirus; atherosclerosis; coagulation system; fibrinolysis; gene therapy; hemostasis; plasminogen system; restenosis; transgenic mice

Indexed keywords

ADENOVIRUS; ANIMAL MODEL; ATHEROSCLEROSIS; BLOOD CLOTTING; FIBRINOLYSIS; GENE THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

EID: 0030481454     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-999055     Document Type: Review

References (131)

1. Edgington TS, N Mackman, K Brand, W Ruf: The structural biology of expression and function of tissue factor. Thromb Haemostas 66:67-79, 1991.
2. Furie B, BC Furie: The molecular basis of blood coagulation. Cell 53:505-518, 1988.
3. Davie E: Biochemical and molecular aspects of the coagulation cascade. Thromb Haemostas 74:1-6, 1995.
4. Esmon CT: The protein C anticoagulant pathway. Arteriosclerosis Thromb 12:135-145, 1992.
5. Dahlbäck B: New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor Va a pathogenic risk factor for thrombosis. Thromb Haemostas 74:139-148, 1995.
6. Bick RL, M Pegram: Syndromes of hypercoagulability and thrombosis: A review. Semin Thromb Hemostas 20:109-132, 1994.
7. Broze GJ: Tissue factor pathway inhibitor and the revised hypothesis of blood coagulation. Trends Cardiovasc Med 2:72-77, 1992.
8. Hoyer LW: Hemophilia A. N Engl J Med 330:38-47, 1996.
9. Bolton-Maggs PHB, FGH Hill: The rarer inherited coagulation disorders: A review. Blood Rev 9:65-76, 1995.
10. Altieri DC: Xa receptor EPR-1. FASEB J 9:860-865, 1995.
11. Coughlin SR: Molecular mechanisms of thrombin signaling. Semin Hematol 31:270-277, 1994.
12. Astrup T: In: Davidson JF, RM Rowan, MM Samama, PC Desnoyers (Eds): Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 3. Raven Press, New York, 1978, pp 1-57.
13. Collen D, HR Lijnen: Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78:3114-3124, 1991.
14. Vassalli JD, JD Sappino, D Belin: The plasminogen activator/plasmin system. J Clin Invest 88:1067-1072, 1991.
15. Schneiderman J, D Loskutoff: Plasminogen activator inhibitors. Trends Cardiovasc Med 1:99-102, 1991.
16. Wiman B: Plasminogen activator inhibitor 1 in plasma: Its role in thrombotic disease. Thromb Haemostas 74:71-76, 1995.
17. Lawrence DA, D Ginsburg: In: High KA, HR Roberts (Eds): Plasminogen Activator Inhibitors. Dekker, New York, 1995, pp 517-543.
18. Bachmann F: The enigma of PAI-2. Gene expression, evolutionary and functional aspects. Thromb Haemostas 74:172-179, 1995.
19. Martin TJ, EH Allan, S Fukumoto: The plasminogen activator and inhibitor system in bone remodeling. Growth Regul 3:209-214, 1993.
20. Hajjar KA: Cellular receptors in the regulation of plasmin generation. Thromb Haemostas 74:294-301, 1995.
21. Plow EF, T Herren, A Redlitz, LA Miles, JL Hoover-Plow: The cell biology of the plasminogen system. FASEB J 9:939-945, 1995.
22. Vassalli JD: The urokinase receptor. Fibrinolysis 8(Suppl 1):172-181, 1994.
23. Blasi F, M Conese, LB Moller, N Pedersen, U Cavallaro, MV Cubellis, F Fazioli, L Hernandez-Marrero, P Limongi, P Munoz-Canoves, M Resnati, L Rüttininen, N Sidenius, E Soravia, MR Soria, MP Stoppelli, D Talarico, T Teesalu, S Valcamonica: The urokinase receptor: structure, regulation and inhibitor-mediated internalization. Fibrinolysis 8(Suppl 1):182-188, 1994.
24. Dano K, N Behrendt, N Brünner, V Ellis, M Ploug, C Pyke: The urokinase-receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8(Suppl 1):189-203, 1994.
25. Wei Y, DA Waltz, N Rao, RJ Drummond, S Rosenberg, HA Chapman: Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269:32380-32388, 1994.
26. Saksela O, D Rifkin: Cell-associated plasminogen activation: Regulation and physiological functions. Annu Rev Cell Biol 4: 93-126, 1988.
27. Andreasen PA, LI Sottrup-Jensen, L Kjoller, A Nykjaer, SK Moestrys, CM Petersen, J Gliemann: Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Lett 338:239-245, 1994.
28. Capecchi MR: Targeted gene replacement. Sci Am 1994, 34-41.
29. Nagy A: Engineering the mouse genome. Methods Enzymol (in press).
30. Nagy A, J Rossant: Targeted mutagenesis: Analysis of phenotype without germline transmission. J Clin Invest 6:1360-1365, 1996.
31. Carmeliet P, V Ferreira, G Breier, S Pollefeyt, L Kieckens, M Gertsenstein, M Fahrig, A Vandenhoeck, K Harpal, C Eberhardt, C Declercq, J Pawling, L Moons, D Collen, W Risau, A Nagy: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-439, 1996.
32. Mulligan RCM: The basic science of gene therapy. Science 260: 926-932, 1983.
33. Schneider MD, BA French: The advent of adenovirus: Gene therapy for cardiovascular disease. Circulation 88:1937-1942, 1995.
34. Carmeliet P, JM Stassen, D Collen, R Meidell, R Gerard: Adenovirus-mediated gene transfer of rt-PA restores thrombolysis in t-PA deficient mice (submitted).
35. Soifer SJ, KG Peters, J O'Keefe, SR Coughlin: Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development. Am J Pathol 144:60-69, 1994.
36. Luther T, C Flössel, N Mackman, A Bierhaus, M Kasper, S Albrecht, HA Sage, L Iruela-Arispe, H Grossman, A Ströhlein, Y Zhang, PP Nawroth, P Carmeliet, DJ Loskutoff, M Müller: Tissue factor expression during human and mouse development. Am J Pathol 149:101-113, 1996.
37. Imada S, H Yamaguchi, N Nagumo, S Katyanagi, H Iwasaki, M Imada: Identification of fetomodulin, a surface marker protein of fetal development as thrombomodulin by gene cloning and functional assays. Dev Biol 140:113-122, 1990.
38. Healy A, H Rayburn, R Rosenberg, H Weiler: Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci USA 92:850-854, 1995.
39. Carmeliet P, N Mackman, L Moons, S Wyns, I Van Vlaenderen, T Luther, G Breier, A Lissens, E Rosen, M Müller, W Risau, T Edgington, D Collen: Role of the cellular receptor tissue factor in embryonic vessel development. Nature 383:73-75, 1996.
40. Dvorak HF, LF Brown, M Detmar, AM Dvorak: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol 146:1029-1039, 1995.
41. Zhang Y, Y Deng, T Luther, M Müller, R Ziegler, R Waldherr, DM Stern, PP Nawroth: Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94:1320-1327, 1994.
42. Contrino J, G Hair, DL Kreutzer, FR Rickles: In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nature (Medicine) 2:209-215, 1996.
43. Suh TT, K Holmbäck, NJ Jensen, CC Daugherty, K Small, D Simon, SS Potter, JL Degen: Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen deficient mice. Genes Dev 9:2020-2033, 1995.
44. Erickson LA, GJ Fici, JE Lund, TP Boyle, HG Polites, KR Marotti: Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 346:74-76, 1990.
45. Eitzman DT, RD McCoy, X Zheng, WP Fay, T Shen, D Ginsburg: Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97:232-237, 1996.
46. Heckel JL, EP Sandgren, JL Degen, RD Palmiter, RL Brinster: Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 62:447-456, 1990.
47. Sidenius N: Expression of the aminoterminal fragment of urokinase-type plasminogen activator in transgenic mice. PhD Thesis, University of Copenhagen, Denmark, 1993.
48. Carmeliet P, L Schoonjans, L Kieckens, B Ream, J Degen, R Bronson, R De Vos, JJ van den Oord, D Collen, R Mulligan: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368:419-424, 1994.
49. Carmeliet P, C De Clercq, S Janssen, S Pollefeyt, A Bouché, S Wijns, RC Mulligan, D Collen: Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 genes in mice. Ann NY Acad Sci 748P:367-381, 1995.
50. Bugge TH, MJ Flick, MJ Danton, CC Daugherty, J Romer, K Dano, P Carmeliet, D Collen, JL Degen: Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 93:5899-5904, 1996.
51. Carmeliet P, L Kieckens, L Schoonjans, B Ream, A Van Nuffelen, G Prendergast, M Cole, R Bronson, D Collen, RC Mulligan: Plasminogen activator inhibitor-1 gene deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 92:2746-2755, 1993.
52. Carmeliet P, JM Stassen, L Schoonjans, B Ream, JJ van den Oord, M De Mol, RC Mulligan, D Collen: Plasminogen activator inhibitor-1 gene deficient mice. II Effects on hemostasis, thrombosis and thrombolysis. J Clin Invest 94:2756-2760, 1993.
53. Dewerchin M, A Van Nuffelen, G Wallays, A Bouché, L Moons, P Carmeliet, RCM Mulligan, D Collen: Generation and characterization of urokinase receptor deficient mice. J Clin Invest 97:870-878, 1996.
54. Bugge TH, TT Suh, MJ Flick, CC Daugherty, J Romer, H Solberg, V Ellis, K Dano, JL Degen: The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem 270:16886-16894, 1995.
55. Ploplis V, P Carmeliet, S Vazirzadeh, I Van Vlaenderen, L Moons, E Plow, D Collen: Effects of disruption of the plasminogen gene on thrombosis, growth and health in mice. Circulation 92:2585-2593, 1995.
56. Bugge TH, MJ Flick, CC Daugherty, JL Degen: Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 9:794-807, 1995.
57. Dougherty K, A Yang, J Harris, T Saunders, S Camper, D Ginsburg: Targeted deletion of the murine plasminogen activator inhibitor-2 gene by homologous recombination. Blood 86(Suppl 1): 455 (Abst), 1995.
58. Zheng X, TL Saunders, SA Camper, LC Samuelson, D Ginsburg: Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci USA 92:12426-12430, 1995.
59. Umans L, L Serneels, L Overbergh, K Lorent, F Van Leuven, H Van Den Berghe: Targeted inactivation of the mouse alpha2-macroglobulin gene. J Biol Chem 270:19778-19785, 1995.
60. Herz J, DE Clouthier, RE Hammer: LDL receptor-related protein internalizes and degrades u-PA:PAI-1 complexes and is essential for embryo implantation. Cell 71:411-421, 1992.
61. Richards WG, PM Carroll, RA Kinloch, PM Wassarman, S Strickland: Creating maternal effect mutations in transgenic mice: Antisense inhibition of an oocyte gene product. Dev Biol 160:543-553, 1993.
62. Leonardsson G, XR Peng, K Liu, L Nordström, P Carmeliet, R Mulligan, D Collen, T Ny. Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators. Proc Natl Acad Sci USA 92:12446-12500, 1995.
63. Cui J, TL Saunders, D Ginsburg: Analysis of factor V function by gene targeting in embryonic stem cells. Blood 86(Suppl 1):449 (Abst), 1995.
64. Bi L, AM Lawler, SE Antonarakis, KA High, JD Gearhart, HH Kazazaian Jr: Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nature (Genetics) 10:119-121, 1995.
65. Montgomery RR, JP Scott: Hemostasis: Diseases of the fluid phases. In: Nathan GD, FA Oski (Eds): Haematology of Infancy and Childhood. Saunders, Philadelphia, 1993, pp 1605-1650.
66. Al-Mondhiry H, WC Ehmann: Congenital afibrinogenemia. Am J Hematol 46:343-347, 1994.
67. White GC: Coagulation factors V and VIII: Normal function and clinical disorders. In: Handin RI, SE Lux, TP Stossel, (Eds.): Blood: Principles & Practice of Hematology. Lippincott, Philadelphia, 1995, pp 1151-1180.
68. Fay WP, AD Shapiro, JL Shih, RR Schleef, D Ginsburg: Complete deficiency of plasminogen-activator inhibitor type 1 due to a frameshift mutation. N Engl J Med 327:1729-1733, 1992.
69. Aoki N: Hemostasis associated with abnormalities of fibrinolysis. Blood Rev 3:11-17, 1989.
70. Elliott MJ, BE Faulkner-Jones, H Stanton, JA Hamilton, D Metcalf: Plasminogen activator in granulocyte-macrophage-CSF transgenic mice. J Immunol 149:3678-3681, 1992.
71. Kluft C, G Dooijewaard, JJ Emeis: Role of the contact system in fibrinolysis. Semin Thromb Hemostas 13:50-68, 1987.
72. Plow EF, TS Edgington: An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH. J Clin Invest 56:30-38, 1975.
73. Hamsten A, U de Faire, G Walldius, Y Dahlen, A Szoumusi, C London, M Blombad, B Wiman: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2:3-9, 1987.
74. Robbins KC: Dysplasminogenemias. Enzyme 40:70-78, 1988.
75. Liu AC, RM Lawn: Lipoprotein (a) and atherogenesis. Trends Cardiovasc Med 4:40-44, 1994.
76. Palabrica TM, AC Liu, MJ Aronowitz, B Furie, RM Lawn, BC Furie: Antifibrinolytic activity of apolipoprotein (a) in vivo: Human apolipoprotein (a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nature (Medicine) 1:256-259, 1995.
77. Forrester JS, M Fishbein, R Helfant, J Fagin: A paradigm for restenosis based on cell biology: Clues for the development of new preventive therapies. J Am Coll Cardiol 17:758-769, 1991.
78. Libby P, D Schwartz, E Brogi, H Tanaka, SK Clinton: A cascade model for restenosis. A special case of atherosclerotic progression. Circulation 86(Suppl III):47-52, 1992.
79. Clowes AW, MA Reidy: Prevention of stenosis after vascular reconstruction: Pharmacologic control of intima hyperplasia - A review. J Vasc Surg 13:885-891, 1991.
80. Simpson AJ, NA Booth, NR Moore, B Bennett: Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 44:139-143, 1991.
81. Clowes AW, MM Clowes, YPT An, MA Reidy, D Belin: Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 67:61-67, 1990.
82. Jackson CL, MA Reidy: The role of plasminogen activation in smooth muscle cell migration after arterial injury. Ann NY Acad Sci 667:141-150, 1992.
83. Jackson CL, EW Raines, R Ross, MA Reidy: Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arteriosclerosis Thromb 13:1218-1226, 1993.
84. Sawa H, S Fujii, BE Sobel: Augmented arterial wall expression of type-1 plasminogen activator inhibitor induced by thrombosis. Arteriosclerosis Thromb 12:1507-1515, 1992.
85. Carmeliet P, D Collen: Physiological consequences of over- or under-expression of fibrinolytic system components in transgenic mice. In: Vadas M, D Harlan (Eds): Vascular Control of Hemostasis: Advances of Vascular Biology (in press).
86. Herbert JM, I Lamarche, V Prabonnaud, F Dol, T Gauthier: Tissue-type plasminogen activator is a potent mitogen for human aortic smooth muscle cells. J Biol Chem 269: 3076-3080, 1994.
87. Carmeliet P, JM Stassen, C Declercq, M Kockx, L Moons, D Collen: A model for arterial neointima formation using perivascular electric injury in mice. Am J Pathol (1997; in press).
88. Carmeliet P, L Moons, M Dewerchin, JM Stassen, C Declercq, R Gerard, D Collen: Receptor-independent role of urokinase-type plasminogen activator in arterial neointima formation in mice (submitted).
89. Carmeliet P, L Moons, I Van Vlaenderen, V Ploplis, EF Plow, D Collen: Role of plasmin proteolysis in arterial neointima formation in mice. J Clin Invest (1997; in press).
90. Yu HR, RM Schultz: Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res, 50:7623-7633, 1990.
91. Wilhelm O, U Weidle, S Hohl, P Rettenberger, M Schmitt, H Graeff: Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator. Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 337:131-134, 1994.
92. Lee SW, ML Kahn, DA Dichek: Expression of an anchored urokinase in the apical endothelial cell membrane. J Biol Chem 267:13020-13029, 1992.
93. Stephens RW, AM Bokman, HT Myöhänen, T Reisberg, H Tapiovaara, N Pedersen, J Grondahl-Hansen, M Llinas, A Vaheri: Heparin binding to the urokinase kringle domain. Biochemistry 31:7572-7579, 1992.
94. Hamsten A, P Eriksson: Fibrinolysis and atherosclerosis: An update. Fibrinolysis 8(Suppl 1):253-262, 1994.
95. Juhan-Vague I, D Collen: On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 2:427-438, 1992.
96. Schneiderman J, MS Sawdey, MR Keeton, GM Bordin, EF Bernstein, RB Dilley, DJ Loskutoff: Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 89:6998-7002, 1992.
97. Schneiderman J, GM Bordin, I Engelberg, R Adar, D Seiffert, T Thinnes, EF Bernstein, RB Dilley, D Loskutoff: Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. J Clin Invest 96:639-645, 1995.
98. Lupu F, DA Heim, F Bachmann, M Hurni, VV Kakkar, EKO Kruithof: Plasminogen activator expression in human atherosclerotic lesions. Arteriosclerosis Thromb Vasc Biol 15:1444-1455, 1995.
99. Grainger DJ, PR Kemp, AC Liu, RM Lawn, JM Metcalfe: Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein (a) mice. Nature 370:460-462, 1994.
100. Bertozzi P, B Astedt, L Zenzius, K Lynch, F LeMaire, W Zapoli, HA Chapman: Depressed bronchioalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 322:890-897, 1990.
101. Tomooka S, WA Border, BC Marshall, NA Noble: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 42:1462-1469, 1992.
102. Kitching R, P Carmeliet, V Ploplis, D Collen, F Plow, ER Holdsworth. P Tipping: Glomerulonephritis in mice with genetic deficiencies of the plasminogen system. J Exp Med (1997; in press).
103. Barazzone C, D Belin, J Huarte, JD Vassalli, AP Sappino: Deleterious role of plasminogen activator inhibitor-1 in response to hyperoxia in mouse. 1996 International Conference, New Orleans.
104. Romer J, TH Bugge, C Pyke, LR Lund, MJ Flick, JL Degen, K Dano: Impaired wound healing in mice with a disrupted plasminogen gene. Nature (Medicine) 2:287-292, 1996.
105. Leloup G, P Lemoine, P Carmeliet, G Vaes: Bone resorption and response to parathyroid hormone or 1.25 dihydroxyvitamin D3 in fetal metatarsals and calvariae from transgenic mice devoid of tissue or urokinase type plasminogen activator or of their inhibitor, PAI-1. J Bone Mineral Res 11:1146-1157, 1996.
106. Bouillon R, E Van Herck, J Verhaeghe, P Carmeliet: Bone metabolism in transgenic mice, deficient in tissue type plasminogen activator. Xth International Congress on Calcium Regulatory Hormones, February 1995, Melbourne, Australia. Bone and Mineral (abstract).
107. Sitrin RG, SB Shollenberger, RM Strieter, MR Gyetko: Endogenously produced urokinase activity amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes. J Leukoc Biol 59:302-311, 1996.
108. Matsushima K, M Taguchi, EJ Kovacs, HA Yound, J Oppenheim: Intracellular localization of human monocytic interleukin-1 (IL-1) activity and release of biologically IL-1 from monocytes by trypsin and plasmin. J Immunol 136:2883-1891, 1986.
109. Auberger P, S Sonthonnax, JF Peyron, B Mari, M Fehlmann: A chymotryptic-type serine proteinase is required for IL-2 production by Jurkat T cells. Immunology 70:547-550, 1993.
110. Gyetko MR, GH Chen, RA McDonald, R Goodman, GB Huffnagle, CC Wilkinson, JA Fuller, GB Toews: Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. J Clin Invest 97:1818-1826, 1996.
111. Tacchini-Cottier F, C Vesin, MM Philippeaux, D Belin, P Vassalli, PF Piguet: Tumor necrosis factor induces platelet activation and consumption in vivo, a process involving urokinase-type plasminogen activator and plasminogen. Abst 6th Int TNF Cong, May 8-12, 1996, Rhodes, Greece.
112. Menoud PA, S Debrot, J Schowing: Roux's Arch Dev Biol 198: 219-226, 1989.
113. Qian Z, ME Gilbert, MA Colicos, ER Kandel, D Kuhl: Tissue-type plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 361:453-457, 1993.
114. Sappino AP, R Madani, J Huarte, D Belin, JZ Kiss, A Wohlwend, JD Vassalli: Extracellular proteolysis in the adult murine brain. J Clin Invest 92:679-685, 1993.
115. Krystosek A, NW Seeds: Plasminogen activator release at the neuronal growth cone. Science 213:1532-1534, 1981.
116. Carroll PM, Tsirka S, WG Richards, MA Frohman, S Strickland: Promoter sequences of the tissue-type plasminogen activator gene are able to confer tissue-specific expression of LacZ during mouse development (in press).
117. Theuring F, A Aguzzi, JD Turner, C Kropp, KD Wohn, S Hoffmann, WD Schleuning: Analysis of human tissue-type plasminogen activator gene promoter activity during embryogenesis of transgenic mice and rats and its induction in the adult mouse brain (submitted).
118. Meiri N, T Masos, K Rosenblum, R Miskin, Y Dudai: Overexpression of urokinase-type plasminogen activator in transgenic mice is correlated with impaired learning. Proc Natl Acad Sci USA 91:3196-3200, 1994.
119. Huang YY, ME Bach, DP Wolfer, M Zhuo, HP Lipp, RD Hawkins, L Schoonjans, JM Godfraiend, ER Kandel, RC Mulligan, D Collen, P Carmeliet: Selective interference with a late stage of both Schaffer collateral and mossy fiber long term potentiation in mice lacking the gene encoding tissue-type plasminogen activator (Proc Natl Acad Sci USA).
120. Frey U, M Müller, D Kühl: A different form of long-lasting potentiation revealed in tissue plasminogen activator mutant mice. J Neurosci 16:2057-2063, 1996.
121. Tsirka SE, A Gualandris, DG Amaral, S Strickland: Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 377:340-344, 1995.
122. Seeds NW, S Haffke, K Christensen, J Schoonmaker: Cerebellar granule cell migration involves proteolysis. In: Lander JM (Ed): Molecular Aspects of Development and Aging of the Nervous System, Plenum Press, New York, 1990, pp 169-178.
123. Nakajima K, M Reddington, S Kohsaka, GW Kreutzberg: Induction of urokinase-type plasminogen activator in rat facial nucleus by axotomy of the facial nerve. J Neurochem 66:2500-2505, 1996.
124. Reddington M, C Haas, GW Kreutzberg: The plasminogen activator system in neurons and glia during motoneuron regeneration. Neuropathol Appl Neurobiol 20:188-190, 1994.
125. 125I-tissue type plasminogen activator binding to cerebellar granule neurons. J Cell Biol 109:265-271, 1989.
126. Jänicke F, M Schmitt, H Graeff: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemostas 17:303-312, 1991.
127. Poggi A, E Bellelli, R Carmela, MP Castelli, L Salvatore, R Marinacci, LA Erickson, M Benedetta Donati, A Bini: Reduced pulmonary metastases of Lewis lung carcinoma in mice transgenic for the plasminogen activator inhibitor-1 gene (submitted).
128. Ploplis V, E French, P Carmeliet, D Collen, E Plow: The plasminogen system and cell migration during an inflammatory response. XIIIth International Congress on Fibrinolysis and Thrombolysis, Barcelona, June 24-28, 1996. Fibrinolysis Suppl.
129. Wagner EF: On transferring genes into stem cells and mice. EMBO J 9:3024-3032, 1990.
130. Botteri FM, H Van der Putten, B Rajput, K Ballmer-Hofer, Y Nagamine: Induction of the urokinase-type plasminogen activator gene by cytoskeleton-disrupting agents. In: Festoff BW (Ed): Serine Proteases and Their Serpin Inhibitors in the Nervous System, Plenum Press, New York, 1990, pp 105-114.
131. Declercq P, P Carmeliet, M Verstreken, F Decock, D Collen: Monoclonal antibodies raised against the targeted proteins in gene-inactivated mice. J Biol Chem 270:8397-8400, 1995.